Gift of Life Biologics and Cellex Celebrated Successful Partnership 

• Gift of Life Biologics and Cellex Cell Professionals have maintained a successful collaboration since 2022 to supply and manufacture cell and gene therapy products.

• The partnership focuses on customised cellular starting materials aligned with complex donor specifications to produce high-quality final drug products.

Gift of Life Biologics and Cellex Cell Professionals have announced the ongoing success of their strategic partnership, which began in 2022. The collaboration focuses on supplying high-quality, customised cellular starting materials for the production of advanced cell and gene therapies (CGT).

The cooperation has enabled Cellex, a Contract Development and Manufacturing Organization (CDMO) with over a decade of experience in CGT, to meet complex donor specifications required by clients. Gift of Life Biologics provides these materials from its FDA HCT/P registered and EMA GMP certified facility in the US, aligning with regulatory standards for high-quality drug production.

The alliance combines the donor sourcing capabilities of Gift of Life Biologics with Cellex’s final drug product manufacturing expertise. This integrated approach ensures a seamless process from cellular material procurement to finished therapeutic products. “Although we have our own collection center and donor database… this partnership is crucial to meeting all our customers’ requests concerning donor specifications,” said Carla Kreissig, Managing Director & CMO of Cellex.

With operations focused in the US and Europe, both companies aim to support the global development and commercialisation of transformative therapies. The partnership highlights the importance of a reliable supply chain and logistics in enabling CGT innovation.

Looking ahead, the firms plan to deepen their collaboration, positioning their integrated platform to support emerging needs in the CGT sector while maintaining quality, expertise, and patient focus.